Expert Consensus on Patient Derived Tumor Organoid Culture and Drug Sensitivity Testing

Authors

  • Zhibing Wu Cancer Center, Zhejiang Hospital Affiliated to Zhejiang University School of Medicine
  • Shigang Ding Department of Gastroenterology, Peking University Third Hospital
  • Xinyu Hao Department of Traditional Chinese Medicine, Peking University Third Hospital
  • Kun Han Department of Medical Oncology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
  • Bing Xia Department of Thoracic Cancer, Hangzhou Cancer Hospital
  • Yuedong He Department of Gynecology, West China Second Hospital, Sichuan University
  • Lin Li Department of Gynecology, West China Second Hospital, Sichuan University
  • Bin Zhang Department of Obstetrics & Gynecology, The First Affiliated Hospital of Fujian Medical University
  • Jiyan Liu Department of Biotherapy, West China Hospital, Sichuan University
  • Xueqin Chen Department of Oncology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University
  • Shi Chen Department of Hepatopancreatobiliary Surgery, Fujian Provincial Hospital
  • Batuer Aikemu Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
  • Mingting Peng National Center for Clinical Laboratories
  • Xianghua Yi Department of Pathology, Tongji Hospital, School of Medicine, Tongji University
  • Huayang Xing Hangzhou AimingMed Technologies Co., Ltd
  • Liming Cheng Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
  • Jing Peng Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
  • Kun Deng Department of Clinical Laboratory,The Third Affiliated Hospital of Chongqing Medical University
  • Maohua Zhou Department of Clinical Laboratory, The Affiliated Panyu Central Hospital of Guangzhou Medical University
  • Jinbo Liu Department of Clinical Laboratory, The First Affiliated Hospital of Southwest Medical University
  • Chong Xu Department of Clinical Hematology and Osology, Shanghai Center for Clinical Laboratory
  • Fang Chen Department of Clinical Laboratory, Second People's Hospital of Jiangyou
  • Tieying Hou Shenzhen Nanshan People's Hospital
  • Xiaoqin Li Department of Clinical Laboratory, Urumqi Maternal and Child Health Hospital
  • Fengbo Zhang Department of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical University
  • Tao Li Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University
  • Zhirong Yang Department of Pathology, Deyang People's Hospital
  • Yiwen Zhou Department of Clinical Laboratory, Shenzhen Hospital of Southern Medical University
  • Yang Luo Department of Laboratory Medicine, Chongqing General Hospital, Chongqing University
  • Hongyu Sun Central Laboratory,The General Hospital of Western Theater Command
  • Zhenyu Yang Department of Pharmacy, Shanghai Clinical Research and Trial Center
  • Zhanying Hong School of Pharmacy, Naval Medical University
  • Mingliang You Hangzhou AimingMed Tumor Organoids Enterprise High-tech Research and Development Center
  • Chongyang Shen Chengdu University of Traditional Chinese Medicine
  • Xiao Zhang Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences
  • Yi Zhou Hangzhou AimingMed Technologies Co., Ltd
  • Quansheng Gao Military Medical Sciences Academy
  • Jing Li Chengdu AimingMed Medical Laboratory
  • Bing Chen Chengdu AimingMed Medical Laboratory
  • Li Yang Chengdu AimingMed Medical Laboratory
  • Xin Lin Chengdu AimingMed Medical Laboratory
  • Hui Li Chengdu AimingMed Medical Laboratory
  • Jialin Gou Chengdu AimingMed Medical Laboratory
  • Dan Xia Chengdu AimingMed Medical Laboratory
  • Jiali Fan Chengdu AimingMed Medical Laboratory
  • Lijuan Wu School of Medicine, Southwest Jiaotong University, Department of Translational Medicine,The General Hospital of the Western Theater Command, China Quality Association for Pharmaceuticals

DOI:

https://doi.org/10.62714/EZGC4449

Abstract

The precision treatment of cancer has consistently been a significant issue in clinical management as well as medical research. With the rapid development and advances towards clinical application of organoids technology, the use of organoids derived from both normal and cancer tissues for pathophysiology studies, treatment regimen development, and drug screening has become increasingly prevalent. This document compiles insights from dozens of nationwide experts and scholars in the field of tumor organoids drug sensitivity testing. It discusses the entire process of tumor organoids drug sensitivity testing, with the intent to provide expert guidance for laboratories interested in conducting clinical testing and application research related to cancer precision therapy.

Downloads

Published

2024-10-28 — Updated on 2024-11-04

How to Cite

[1]
Wu, Z., Ding, S., Hao, X., Han, K., Xia, B., He, Y., Li, L., Zhang, B., Liu, J., Chen, X., Chen, S., Aikemu, B. , Peng, M., Yi, X., Xing, H., Cheng, L., Peng, J., Deng, K., Zhou, M., Liu, J., Xu, C., Chen, F., Hou, T., Li, X., Zhang, F., Li, T., Yang, Z., Zhou, Y., Luo, Y., Sun, H., Yang, Z., Hong, Z., You, M., Shen, C., Zhang, X., Zhou, Y., Gao, Q., Li, J., Chen, B., Yang, L., Lin, X., Li, H., Gou, J., Xia, D., Fan, J. and Wu, L. 2024. Expert Consensus on Patient Derived Tumor Organoid Culture and Drug Sensitivity Testing. Journal of Organoid and Bioscience. 2, 2 (Nov. 2024), 1–28. DOI:https://doi.org/10.62714/EZGC4449.

Issue

Vol. 2 No. 2 (2024): Special Issue

Section

Articles